Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AssigneeImmune Pharmaceuticals Ltd.
InventorDaniel TEPER
Life of this patent
Estimating the term…
Abstract
The present invention provides use of one or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains in non-native antibody framework regions, or, alternatively, the whole VH, VL, or CAT-212 antibody, in treating inflammatory diseases in a subject, such as inflammatory bowel disease.
Claims17
-11. (canceled)
A method for treating an inflammatory bowel disease in a subject, comprising administering to said subject a composition comprising a specific binding member that binds human eotaxin, wherein said binding member comprises an antibody VH domain and an antibody VL domain, wherein the CDR1 domain of said antibody VH domain consists of the amino acid sequence as set forth in SEQ ID NO:
- 5, the CDR2 domain of said antibody VH domain consists of the amino acid sequence as set forth in SEQ ID NO:
- 6, and the CDR3 domain of said antibody VH domain consists of the amino acid sequence as set forth in SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.